A phase I study of ultra-low dose subcutaneous interleukin-2 (IL-2) for treatment of refractory chronic graft versus host disease
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 19 Dec 2018
At a glance
- Drugs Interleukin-2 (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions
- 25 Nov 2018 Planned End Date changed from 1 Aug 2018 to 1 Aug 2019.
- 31 Aug 2018 Biomarkers information updated
- 03 Oct 2017 Planned End Date changed from 1 Aug 2017 to 1 Aug 2018.